The co-localizing Zorya II, Druantia III, and ARMADA II defense systems on O-island 172 confer synergistic anti-phage defense in enterohemorrhagic Escherichia coli.

Co-localized Zorya II, Druantia III, and ARMADA II systems on O-island 172 provide synergistic phage resistance in Escherichia coli strain EDL933, with Druantia III and ARMADA II being most effective.

• Why it matters: Understanding bacterial defense mechanisms against phages is crucial for developing effective phage therapies, especially for pathogenic strains like EHEC that resist current treatments and pose serious health risks.
• What they did: The study analyzed 426 E. coli strains carrying these defense systems, used gene deletion mutants and efficiency of plating assays to assess their individual and combined effects against diverse phages, revealing significant synergy between Druantia III and ARMADA II.
• The result: Druantia III and ARMADA II together confer broad and robust phage resistance, suggesting that targeting their anti-defense proteins could enhance phage therapy effectiveness against EHEC infections.